Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Octenidine Dihydrocloride in aqueous · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Investigational Product | EXPERIMENTAL | Polyester cloth impregnated with investigational product |
| Vehicle Control (VC) | PLACEBO_COMPARATOR | Polyester cloth impregnated with the vehicle control |
| Saline Control (SC) | PLACEBO_COMPARATOR | Saline applied wtih polyester cloth |
| Name | Type | Description |
|---|---|---|
| Octenidine Dihydrocloride in aqueous solution | DRUG | application of investigational product |
| Vehicle Control | OTHER | application of vehicle control |
| Saline Control | OTHER | application of placebo |
Inclusion Criteria: * Males and/or females, at least 18 years or older and of any race. * Are in good general health. * Unable to become pregnant, or willing to use an acceptable method of contraception (i.e. oral contraception, intra-uterine device \[IUD\], diaphragm, condom, abstinence, bilateral...
Octenidine Dihydrocloride in aqueous is used for preoperative skin preparation, a dermatology indication. It is being developed as an antimicrobial cloth to reduce skin bacteria before surgical procedures. The drug is currently in Phase 2 clinical development and is being studied in a completed clinical trial in the United States.
Octenidine Dihydrocloride in aqueous is being developed by Becton, Dickinson and Company, which trades under the ticker BDX. The company is conducting clinical research on this small molecule for preoperative skin preparation. The drug is currently in Phase 2 development.
Octenidine Dihydrocloride in aqueous is in Phase 2 clinical development. It is an investigational drug for preoperative skin preparation and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug remains under clinical investigation.
Octenidine Dihydrocloride in aqueous has one completed clinical trial, NCT03229759, titled 'Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth.' This Phase 2 study enrolled 99 participants in the United States, was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.
Octenidine Dihydrocloride in aqueous is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for preoperative skin preparation. The drug has completed one clinical trial, but it has not yet received regulatory approval for marketing.